TG Therapeutics, Inc. (TGTX)
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event for TG's most important clinical development program. SC Briumvi's bioavailability, safety, and tolerability support expectations of non-inferiority to IV Briumvi, with phase 3 topline data expected late 2026 or early 2027. IV Briumvi's sequential growth has improved, with 2026 U.S. sales guidance raised to $885–900 million and with potential for beat-and-raise trends to continue.
TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook
TG Therapeutics remains a "Strong Buy" as BRIUMVI drives robust revenue growth and pipeline expansions. The company raised 2026 BRIUMVI sales guidance to $885–$900 million, reflecting 63% year-over-year Q1 sales growth and strong market momentum. Phase 3 ENHANCE trial success with single 600 mg IV BRIUMVI dosing supports label expansion and competitive positioning in the RMS market.
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
Historic Signal Says This Biotech Outperforms
TG Therapeutics Inc (NASDAQ:TGTX) is trading down 1.2% at $42.35, after last week being rejected by the overhead $44 ceiling.
